The Food and Drug Administration (FDA) is intensively examining seven peptide substances, an area that has seen a rise in popularity due to claimed health advantages. Scheduled meetings for July 23 and 24 at the FDA’s White Oak Campus in Silver Spring, Maryland, will see the FDA’s Pharmacy Compounding Advisory Committee evaluate whether these peptides should feature on the agency’s 503A Bulks List, which would sanction their use in some compounded prescription medications.
Although these peptides lack FDA approval, they are readily accessible through wellness clinics, compounding operations, and online sellers classified as part of a gray market.
The Health and Human Services Secretary, Robert F. Kennedy Jr., expressed his endorsement for broadening access to certain peptide therapies. Meanwhile, FDA reviewers have voiced concerns about the scant evidence backing the safety and efficacy of the seven substances under review.
Reuters has indicated that consumer interest is expected to remain robust regardless of the committee’s decision, driven by peptides’ burgeoning popularity in areas like weight loss, muscle building, performance enhancement, chronic disease management, and wound repair.
Peptides Under FDA Scrutiny
- BPC-157: Proposed use for ulcerative colitis; available in oral capsules, nasal spray, injections, transdermal cream, and rectal suppository forms.
- TB-500: Proposed for wound healing; forms include subcutaneous or intramuscular injection.
- KPV: Aimed at wound healing and inflammatory conditions; available as cream and gel.
- MOTS-c: Intended for obesity and osteoporosis; available as subcutaneous injection.
- Semax: Proposed for cerebral ischemia, migraine, and trigeminal neuralgia; administered via intranasal spray and subcutaneous injection.
- Emideltide: Targets opioid withdrawal, chronic insomnia, and narcolepsy; administered as subcutaneous injection.
- Epitalon: Intended for insomnia; available as subcutaneous injection.
Expert Insights and Concerns
Dr. Alex Tatem, a performance medicine and peptide expert, will present his perspectives at this important FDA forum. An Indiana-based board-certified urologist, Tatem strongly believes in the potential of the products under discussion, each addressing distinct patient issues.
He emphasized the safety of compounds like BPC-157 and TB-500, referencing studies that deem them safe. In contrast, over-the-counter medications such as ibuprofen, widely used for pain relief, can lead to severe side effects like stomach bleeding and kidney damage if used excessively.
Dr. Marc Siegel, Fox News’ senior medical analyst, insisted on a thorough study, indicating skepticism regarding the completeness of existing data supporting these peptides.
Looking Ahead
Dr. Tatem anticipates a challenging debate but remains hopeful that committee members will consider real-world data, reflecting low adverse event rates from millions of doses administered between 2014 and 2023.
If the committee approves these substances, the FDA must still carry out comprehensive reviews and rulemaking before adding any to the 503A Bulks List. The urgency lies in affording patients supervised access to prescriptions once the rulemaking concludes.
Tatem urges public engagement, stressing the value of individual voices amid the committee’s recommendations to the FDA. Encouraging outreach to local representatives for peptides’ safe, regulated access, Tatem underscores the potential impact the public’s opinions could have.
Fox News Digital sought comments from the FDA and ibuprofen manufacturer Haleon, aiming to broaden insight into these ongoing matters.
Leave a Reply